Trogenix
Edinburgh
About Trogenix
Trogenix develops precision genetic medicines using its Odysseus platform, which harnesses Synthetic Super-Enhancers (SSEs) to distinguish cancer cell states from healthy ones and drive selective payload delivery. Its methodology combines controlled cell killing, immune modulation, and long-term protection against recurrence. The company pursues therapeutic programmes in aggressive solid tumours, notably glioblastoma, and explores expansion into colorectal liver metastases, hepatocellular carcinoma, and lung cancer. Trogenix also partners with manufacturing and development specialists (e.g. Viralgen) to accelerate production of its gene therapy assets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $113.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2025)
- Website: trogenix.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/trogenix-19190 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.